Disposición ANMAT 5461/2026: Updated Fee Framework for Argentina

Updated: 2026-11-12 · GRZAN Regulatory Team · Verification date 2026-10-20

1. Key takeaways

Disposición ANMAT 5461/2026 updates the fee framework and applies from September 1, 2026 to procedures initiated on or after that date. September 1, 2026 is therefore a clear dividing point: procedures initiated before that date remain subject to the previous fee standards, while procedures initiated on or after it fall under the new standards. The rule is temporal, not retroactive — it does not recalculate fees for dossiers already under review.

For companies, the practical consequences are threefold: ① budgets must be recalculated against the new standards; ② where a project can be brought forward, there is legitimate room to choose the timing of initiation; ③ the fee framework update also concerns the fee cap applied to rate-based import intervention reviews. Each of these consequences rewards early planning: the first affects finance, the second affects project scheduling, and the third affects the cost model for physical imports entering the country.

2. Legal basis

RegulationReference numberPublication dateRelevant provisions
Fee framework updateDisposición ANMAT 5461/2026Applicable from September 1, 2026 to newly initiated proceduresFee schedule provisions; fee cap provisions for import intervention reviews
Legal basis for feesDisposición ANMAT 2319/2002 (T.O. 2004) and its amendments2002 (2004 consolidated text)Fee schedule provisions
RPPTM registry annual maintenance feeDisposición ANMAT 5634/20242024Annual maintenance fee provisions
Import facilitation for Class I/II productsDisposición ANMAT 4446/2025Published June 24, 2025, effective 30 days after publicationImport-stage provisions

3. Expert insights

Insight 1: Applicable to newly initiated procedures is a point-in-time rule, not a recalculation of everything under review. Procedures formally initiated before September 1, 2026 are not affected by the new standards. This gives companies a concrete scheduling consideration: if the dossier is ready, initiating before the dividing point locks in the fees under the old standards. The reverse also holds — a project that slips past the date for unprepared reasons cannot claim the old fees, so the readiness of documentation, not intention, determines which standard applies.

Insight 2: The fee framework includes a cap on import intervention review fees. This detail is worth noting: ANMAT has set a fee ceiling for import intervention reviews that are charged on a rate basis. However, the existence of the cap does not decide whether a given shipment will be subject to intervention review — the two are independent judgments. A company cannot assume that a review will occur, or will not occur, simply because a cap exists. The cap bounds the cost if a review happens; it says nothing about the likelihood of the review itself.

Insight 3: Peso denomination combined with inflation strips multi-year fee forecasts of meaning. In Argentina’s macroeconomic environment, any fee forecast spanning more than one year can serve only as an order-of-magnitude reference. The more pragmatic approach is to book official fees as a floating item and pay whatever the fee schedule in force at the moment of filing actually states. Companies that instead fix fee numbers in long-term contracts transfer currency and adjustment risk to whoever signed the fixed number — usually the service provider or, ultimately, the manufacturer through a premium.

Insight 4: The dividing point rewards documentation readiness more than any negotiating tactic. Because the standard that applies is fixed by the initiation date and not by negotiation, the only lever a company genuinely controls is when the dossier is complete enough to be filed. Teams that track the fee update as a project milestone can legitimately save cost by accelerating final document checks, translations, and internal sign-offs; teams that discover the dividing point after the fact have no remedy. This is also why the update should appear in the compliance calendar of every subsidiary and importer working on Argentine registrations, not only in the budget spreadsheet of the finance department.

4. Practical recommendations

  1. Schedule projects around the September 1, 2026 dividing point. For projects whose documents are ready, evaluate whether initiation can take place before the dividing point; for projects that are not ready, budget against the new standards from the outset.
  2. Check the current fee schedule at the moment of filing. Do not pay on the basis of historical figures; rely on the fee schedule currently published by ANMAT.
  3. Include import intervention review fees in the import cost model. A fee cap exists, but whether a review actually occurs must be judged separately by cargo category — do not conflate the ceiling with the trigger.
  4. Include a floating official-fee clause in customer quotations. State that official fees are settled at the amount actually incurred, so that exchange-rate and adjustment risk is not borne unilaterally by the service provider.

The common thread across these four actions is that Disposición ANMAT 5461/2026 should be treated as a scheduling event, not merely as a pricing event. The regulation itself is stable once read — its fee schedule provisions and its fee cap provisions for import intervention reviews replace the prior basis going forward — while the uncertainty lives entirely in timing and currency. A company that fixes the timing decisions and the floating-fee mechanics early will experience the update as a planned cost transition; one that postpones both will experience it as a series of surprises in procurement, logistics, and customer invoicing at once.

5. Verification checklist

  • □ Confirmed that 5461/2026 applies from September 1, 2026 to newly initiated procedures
  • □ Project initiation timing evaluated against the dividing point
  • □ ANMAT’s current fee schedule checked before filing
  • □ Import intervention review fees included in the import cost model
  • □ Understood that the fee cap and the occurrence of a review are two independent judgments
  • □ Floating official-fee clause included in customer quotations

Regulatory information verified as of October 29, 2026.

In Argentina, GRZAN operates a wholly-owned subsidiary that can serve as the registration holder and importer for foreign manufacturers, directly handling classification determination, pathway selection, GMP and CFS documentation chains, Spanish-language technical documentation and label localization, HELENA submissions and deficiency responses, as well as BONITA import notifications, ARGOS vigilance system operation, change maintenance, and 5-year renewal planning.

The GRZAN regulatory team consists of professionals with many years of hands-on international registration experience and tracks the dynamics of regulatory authorities across countries on an ongoing basis. All external content follows the drafting standard of conclusions first, traceable bases, and verifiable figures. For an Argentina or MERCOSUR market access plan tailored to a specific product, contact the GRZAN regulatory team at info@grzanglobal.com.

Disclaimer

Prepared by GRZAN from publicly available regulation. It is provided for general information only and does not constitute legal advice. Legislation and official fees are subject to change by the competent authority.

About GRZAN

GRZAN (Global Regulatory Zone Access Navigator) — the global market-access navigator for medical devices and IVDs.

GRZAN is a specialist consultancy for medical device and IVD market access, providing end-to-end regulatory solutions across the product lifecycle and making international market entry simpler and faster.

Key figures. More than 25 wholly owned subsidiaries worldwide covering 50+ countries and regions; chosen by 100+ listed and leading Chinese device manufacturers, with 4,000+ successful cases; 12+ years in the sector and 200+ regulatory training sessions and seminars delivered.

What we do. Global market access: multi-country registration programmes, technical documentation, regulatory advice. Clinical evidence: clinical evaluation reports (CER), usability studies, overseas clinical investigations. Quality systems: ISO 13485, MDSAP, FDA QMSR and BGMP implementation and audit readiness. Authorised representative and licence-holder services across Southeast Asia, Latin America, the Middle East, Africa, Europe and North America.

Why GRZAN. A real operating entity, with the certificate held by the manufacturer: our direct overseas subsidiaries act as the compliant local holder, so the regulatory relationship stays clear and you keep control rather than being tied to a distributor. Direct access to the team: no time-zone gap, no language barrier, no cultural gap. Review points anticipated: we know what FDA 510(k), EU MDR, Southeast Asian, Latin American and Middle Eastern reviewers look for, which shortens timelines and reduces deficiency letters. Pathway planning: pre-decision analysis and risk assessment before you commit.

Every engagement rests on three commitments: efficiency through pre-submission review, certainty through a clear pathway, and stability through a licence-holder that stays in place.

Take your devices global with GRZAN

We work with manufacturers worldwide to open new markets with a clear regulatory pathway.

Contact us
WhatsApp
QR Code
WhatsApp QR Code
Scan to chat on WhatsApp
Phone
Call
Office Mon-Fri 9:00-18:00
0755-88659477
Mobile 24/7 Service
+86 15816864648
Email
Mail